Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.54
MRK's Cash-to-Debt is ranked lower than
71% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. MRK: 0.54 )
Ranked among companies with meaningful Cash-to-Debt only.
MRK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 0.74 Max: N/A
Current: 0.54
Equity-to-Asset 0.41
MRK's Equity-to-Asset is ranked lower than
77% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
MRK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.45 Max: 0.53
Current: 0.41
0.34
0.53
Interest Coverage 9.22
MRK's Interest Coverage is ranked lower than
75% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. MRK: 9.22 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 10.18 Max: 20.13
Current: 9.22
4.14
20.13
Piotroski F-Score: 7
Altman Z-Score: 3.27
Beneish M-Score: -2.66
WACC vs ROIC
7.21%
9.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 16.23
MRK's Operating Margin % is ranked higher than
70% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. MRK: 16.23 )
Ranked among companies with meaningful Operating Margin % only.
MRK' s Operating Margin % Range Over the Past 10 Years
Min: 6.43  Med: 16.53 Max: 21.86
Current: 16.23
6.43
21.86
Net Margin % 10.88
MRK's Net Margin % is ranked higher than
63% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. MRK: 10.88 )
Ranked among companies with meaningful Net Margin % only.
MRK' s Net Margin % Range Over the Past 10 Years
Min: 1.87  Med: 13.05 Max: 47.03
Current: 10.88
1.87
47.03
ROE % 10.30
MRK's ROE % is ranked higher than
58% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. MRK: 10.30 )
Ranked among companies with meaningful ROE % only.
MRK' s ROE % Range Over the Past 10 Years
Min: 1.51  Med: 11.48 Max: 42.27
Current: 10.3
1.51
42.27
ROA % 4.47
MRK's ROA % is ranked higher than
53% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. MRK: 4.47 )
Ranked among companies with meaningful ROA % only.
MRK' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 5.9 Max: 16.34
Current: 4.47
0.79
16.34
ROC (Joel Greenblatt) % 43.21
MRK's ROC (Joel Greenblatt) % is ranked higher than
80% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. MRK: 43.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MRK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.88  Med: 44.45 Max: 105.49
Current: 43.21
10.88
105.49
3-Year Revenue Growth Rate -0.90
MRK's 3-Year Revenue Growth Rate is ranked lower than
73% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. MRK: -0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MRK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.5  Med: 8.4 Max: 22.8
Current: -0.9
-16.5
22.8
3-Year EBITDA Growth Rate -4.50
MRK's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. MRK: -4.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MRK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 8.1 Max: 44.8
Current: -4.5
-17.6
44.8
3-Year EPS without NRI Growth Rate -1.40
MRK's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. MRK: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: 12.2 Max: 73.8
Current: -1.4
-29.3
73.8
» MRK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MRK Guru Trades in Q2 2016

Tom Gayner 5,600 sh (New)
Jim Simons 2,926,534 sh (+504.24%)
Richard Pzena 1,415,390 sh (+53.62%)
Ray Dalio 251,546 sh (+19.36%)
Ken Fisher 6,759,345 sh (+0.91%)
Mairs and Power 102,164 sh (+0.31%)
Jeff Auxier 153,303 sh (unchged)
Robert Bruce 259,400 sh (unchged)
David Dreman 710 sh (unchged)
Murray Stahl 45,497 sh (unchged)
David Carlson 250,000 sh (unchged)
Tom Russo Sold Out
John Burbank Sold Out
Barrow, Hanley, Mewhinney & Strauss 26,516,070 sh (-0.55%)
Dodge & Cox 24,372,814 sh (-0.70%)
John Buckingham 25,676 sh (-0.81%)
PRIMECAP Management 2,967,700 sh (-0.84%)
Kahn Brothers 964,925 sh (-2.08%)
Pioneer Investments 901,916 sh (-2.54%)
Charles Brandes 2,891,914 sh (-3.60%)
Mario Gabelli 113,505 sh (-3.93%)
Vanguard Health Care Fund 46,499,820 sh (-4.57%)
Richard Snow 848,738 sh (-6.84%)
Ruane Cunniff 3,981 sh (-18.66%)
Manning & Napier Advisors, Inc 404,399 sh (-19.37%)
T Rowe Price Equity Income Fund 3,500,000 sh (-25.58%)
First Eagle Investment 7,790 sh (-51.58%)
Joel Greenblatt 540,222 sh (-56.73%)
Paul Tudor Jones 3,900 sh (-99.45%)
» More
Q3 2016

MRK Guru Trades in Q3 2016

Jeremy Grantham 7,500 sh (New)
Stanley Druckenmiller 683,800 sh (New)
Steven Cohen 179,800 sh (New)
Tweedy Browne 3,306 sh (New)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (New)
Paul Tudor Jones 612,800 sh (+15612.82%)
David Carlson 275,000 sh (+10.00%)
Ken Fisher 6,817,544 sh (+0.86%)
Tom Gayner 5,600 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
David Dreman 710 sh (unchged)
Murray Stahl 45,497 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ray Dalio Sold Out
Ruane Cunniff Sold Out
Signature Select Canadian Fund Sold Out
Jeff Auxier 153,153 sh (-0.10%)
PRIMECAP Management 2,964,300 sh (-0.11%)
John Buckingham 25,560 sh (-0.45%)
Richard Pzena 1,408,678 sh (-0.47%)
Kahn Brothers 957,991 sh (-0.72%)
Charles Brandes 2,812,318 sh (-2.75%)
T Rowe Price Equity Income Fund 3,375,000 sh (-3.57%)
Mairs and Power 96,933 sh (-5.12%)
Mario Gabelli 107,405 sh (-5.37%)
Richard Snow 792,347 sh (-6.64%)
Vanguard Health Care Fund 41,516,228 sh (-10.72%)
Manning & Napier Advisors, Inc 335,976 sh (-16.92%)
Dodge & Cox 18,327,311 sh (-24.80%)
Barrow, Hanley, Mewhinney & Strauss 18,581,032 sh (-29.93%)
Pioneer Investments 602,479 sh (-33.20%)
Joel Greenblatt 330,785 sh (-38.77%)
Jim Simons 1,303,400 sh (-55.46%)
» More
Q4 2016

MRK Guru Trades in Q4 2016

Jeremy Grantham 13,700 sh (+82.67%)
John Buckingham 31,185 sh (+22.01%)
Manning & Napier Advisors, Inc 379,630 sh (+12.99%)
Murray Stahl 47,880 sh (+5.24%)
Mairs and Power 97,839 sh (+0.93%)
Pioneer Investments 606,522 sh (+0.67%)
Jeff Auxier 153,453 sh (+0.20%)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
David Carlson 275,000 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
David Dreman 710 sh (unchged)
Stanley Druckenmiller 683,800 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
Tweedy Browne Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,959,100 sh (-0.18%)
Ken Fisher 6,802,264 sh (-0.22%)
Kahn Brothers 952,741 sh (-0.55%)
Mario Gabelli 106,605 sh (-0.74%)
Charles Brandes 2,690,441 sh (-4.33%)
Barrow, Hanley, Mewhinney & Strauss 17,668,105 sh (-4.91%)
Richard Pzena 1,260,853 sh (-10.49%)
Joel Greenblatt 287,063 sh (-13.22%)
Vanguard Health Care Fund 35,181,618 sh (-15.26%)
Dodge & Cox 13,947,142 sh (-23.90%)
Richard Snow 407,174 sh (-48.61%)
Paul Tudor Jones 9,900 sh (-98.38%)
» More
Q1 2017

MRK Guru Trades in Q1 2017

Jim Simons 7,363,034 sh (New)
Tweedy Browne 3,306 sh (New)
Steven Cohen 155,000 sh (New)
Caxton Associates 7,900 sh (New)
Paul Tudor Jones 168,527 sh (+1602.29%)
Joel Greenblatt 767,331 sh (+167.30%)
PRIMECAP Management 4,875,300 sh (+64.76%)
John Buckingham 32,088 sh (+2.90%)
Manning & Napier Advisors, Inc 383,314 sh (+0.97%)
Ken Fisher 6,862,961 sh (+0.89%)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
Tom Gayner 5,600 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
David Carlson 275,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
David Dreman Sold Out
Stanley Druckenmiller Sold Out
Mario Gabelli 105,805 sh (-0.75%)
Kahn Brothers 940,119 sh (-1.32%)
Pioneer Investments 597,088 sh (-1.56%)
Dodge & Cox 13,689,174 sh (-1.85%)
Jeff Auxier 149,153 sh (-2.80%)
Charles Brandes 2,606,115 sh (-3.13%)
Murray Stahl 46,324 sh (-3.25%)
Mairs and Power 90,144 sh (-7.86%)
Vanguard Health Care Fund 32,271,044 sh (-8.27%)
Barrow, Hanley, Mewhinney & Strauss 15,815,276 sh (-10.49%)
Richard Snow 318,316 sh (-21.82%)
Richard Pzena 826,233 sh (-34.47%)
Jeremy Grantham 7,600 sh (-44.53%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:NVS, NYSE:PFE, NYSE:SNY, OTCPK:RHHBY, OTCPK:BAYRY, OTCPK:GLAXF, NYSE:ABBV, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, NYSE:JNJ, OTCPK:PTKFY, OTCPK:SNPHY » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, infections, and osteoporosis. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Following the Schering acquisition, close to half of the company's sales are generated in the United States.

Top Ranked Articles about Merck & Co Inc

Merck Reports Triple-Combo Results The therapy achieved high success rates in clinical trials with hepatitis C patients
Merck & Co. Inc. (NYSE:MRK) announced through Business Wire on Nov. 14 that the “results from three phase 2 clinical trials evaluating MK-3682B (MK3682/grazoprevir/ruzasvir1), the company’s investigational all-oral, triple-combination regimen" for the treatment of patients who are chronically infected with the hepatitis C virus, are ready to be presented at The Liver Meeting® 2016 Monday (C-CREST 1 & 2 Parts B and C) and Tuesday (C-SURGE). Read more...
Insiders Are Buying Hertz and Selling Merck Largest insider buys and sales of the week
The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$200,000+” duration to November 2016 and All Insider Sales to “$5,000,000+”. Read more...
Merck: Promising Results From Immunotherapy Based on Keytruda Merck presented the results of two studies on the first-line treatment of advanced lung cancer
Very promising are the results of two studies on the first-line treatment of advanced lung cancer because of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, presented on Oct. 9 at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark.
Read more...
Sanofi Sues Merck Over Patent Infringement Company trying to prevent further competition, reverse declining sales
French pharmaceutical giant Sanofi SA (NYSE:SNY) filed a lawsuit against Merck & Co. (NYSE:MRK) for supposed patent infringements last Friday. Read more...
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth A low-risk dividend for the short to mid term
From the price to sales point of view, Merck (NYSE:MRK) is one of the most expensive healthcare stocks, trading at nearly 4.5 times sales, more than you need to pay for Pfizer (NYSE:PFE) or Novartis (NYSE:NVS). Merck is possibly the only pharma major to see its stock price almost steadily rise in the last five years. It has more than doubled its price during that time, from under $30 in August 2011 to above $60 in August 2016. Read more...
Revenue and Earnings Higher for Merck in the Second Quarter Merck reports good second quarter results
Merck (NYSE:MRK) reported second quarter earnings on Friday, July 29. The Dow Jones Industrial Average component beat earnings estimates for both revenue and earnings per share. Revenue for the quarter was $9.84 billion, beating estimates by $60 million. Earnings per share for the quarter were 93 cents, beating estimates by 0.02 cents. Read more...
Merck CEO Sells 60,000 Company Shares Company's vice president sells 75,000 shares in 2 transactions
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 60,000 company shares at a per share price of $58.00 on July 5. The total transaction was $3.48 million. Read more...

Ratios

vs
industry
vs
history
PE Ratio 41.62
MRK's PE Ratio is ranked lower than
71% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. MRK: 41.62 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 21.67 Max: 138.33
Current: 41.62
6.33
138.33
Forward PE Ratio 16.78
MRK's Forward PE Ratio is ranked higher than
100% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. MRK: 16.78 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 41.62
MRK's PE Ratio without NRI is ranked lower than
71% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. MRK: 41.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 21.67 Max: 138.33
Current: 41.62
6.33
138.33
Price-to-Owner-Earnings 82.60
MRK's Price-to-Owner-Earnings is ranked lower than
66% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. MRK: 82.60 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.35  Med: 16.59 Max: 84.71
Current: 82.6
6.35
84.71
PB Ratio 4.48
MRK's PB Ratio is ranked lower than
67% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. MRK: 4.48 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.23 Max: 7.25
Current: 4.48
1.72
7.25
PS Ratio 4.53
MRK's PS Ratio is ranked lower than
63% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. MRK: 4.53 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.36 Max: 5.48
Current: 4.53
2.01
5.48
Price-to-Free-Cash-Flow 26.51
MRK's Price-to-Free-Cash-Flow is ranked higher than
57% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. MRK: 26.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.42 Max: 88.07
Current: 26.51
7.88
88.07
Price-to-Operating-Cash-Flow 21.28
MRK's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. MRK: 21.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 13.89 Max: 35.61
Current: 21.28
6.68
35.61
EV-to-EBIT 33.29
MRK's EV-to-EBIT is ranked higher than
98% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. MRK: 33.29 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 16.25 Max: 52.5
Current: 33.29
4.9
52.5
EV-to-EBITDA 17.66
MRK's EV-to-EBITDA is ranked higher than
99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. MRK: 17.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.2 Max: 20.4
Current: 17.66
4.2
20.4
Shiller PE Ratio 29.08
MRK's Shiller PE Ratio is ranked higher than
73% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. MRK: 29.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.27  Med: 16.66 Max: 29.86
Current: 29.08
8.27
29.86
Current Ratio 1.59
MRK's Current Ratio is ranked lower than
65% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. MRK: 1.59 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.51 Max: 3.7
Current: 1.59
0.97
3.7
Quick Ratio 1.33
MRK's Quick Ratio is ranked lower than
61% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. MRK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.19 Max: 3.44
Current: 1.33
0.69
3.44
Days Inventory 146.73
MRK's Days Inventory is ranked lower than
61% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. MRK: 146.73 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 108.49  Med: 130.49 Max: 205.16
Current: 146.73
108.49
205.16
Days Sales Outstanding 64.59
MRK's Days Sales Outstanding is ranked higher than
59% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. MRK: 64.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 59.4 Max: 87.87
Current: 64.59
44.5
87.87
Days Payable 68.00
MRK's Days Payable is ranked higher than
53% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. MRK: 68.00 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 37.12  Med: 47.38 Max: 90.81
Current: 68
37.12
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.86
MRK's Dividend Yield % is ranked higher than
77% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. MRK: 2.86 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.51  Med: 3.64 Max: 6.68
Current: 2.86
2.51
6.68
Dividend Payout Ratio 1.18
MRK's Dividend Payout Ratio is ranked lower than
90% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. MRK: 1.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.85 Max: 5.43
Current: 1.18
0.27
5.43
3-Year Dividend Growth Rate 2.30
MRK's 3-Year Dividend Growth Rate is ranked lower than
65% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 31
Current: 2.3
0
31
Forward Dividend Yield % 2.91
MRK's Forward Dividend Yield % is ranked higher than
80% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. MRK: 2.91 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.33
MRK's 5-Year Yield-on-Cost % is ranked higher than
68% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. MRK: 3.33 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.92  Med: 4.24 Max: 7.78
Current: 3.33
2.92
7.78
3-Year Average Share Buyback Ratio 2.10
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. MRK: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.1 Max: 2.8
Current: 2.1
-13
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 38.65
MRK's Price-to-Tangible-Book is ranked lower than
96% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. MRK: 38.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MRK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 10.88 Max: 3112.5
Current: 38.65
3.19
3112.5
Price-to-Intrinsic-Value-Projected-FCF 1.55
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. MRK: 1.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.48
Current: 1.55
0.75
3.48
Price-to-Median-PS-Value 1.34
MRK's Price-to-Median-PS-Value is ranked lower than
64% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. MRK: 1.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.19 Max: 2.12
Current: 1.34
0.63
2.12
Price-to-Graham-Number 8.44
MRK's Price-to-Graham-Number is ranked lower than
95% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. MRK: 8.44 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MRK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.25 Max: 31.92
Current: 8.44
1.09
31.92
Earnings Yield (Greenblatt) % 3.00
MRK's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. MRK: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 6.15 Max: 20.6
Current: 3
1.9
20.6
Forward Rate of Return (Yacktman) % 2.95
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. MRK: 2.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.7  Med: 7.2 Max: 20.4
Current: 2.95
-5.7
20.4

More Statistics

Revenue (TTM) (Mil) $39,929
EPS (TTM) $ 1.56
Beta0.95
Short Percentage of Float0.55%
52-Week Range $54.78 - 66.80
Shares Outstanding (Mil)2,735.16

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39,935 40,850 42,678
EPS ($) 3.84 4.21 4.73
EPS without NRI ($) 3.84 4.21 4.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.21%
Dividends per Share ($) 1.86 1.94 1.97
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna May 23 2017 
Osteoporosis Drug Meets Primary and Secondary Endpoints May 23 2017 
Howard Marks on the Truth About Investing May 19 2017 
US Market Indexes Higher on Thursday May 18 2017 
Tweedy Browne Hooks Up Baidu in 1st Quarter May 17 2017 
Nasdaq Closes at 6121, Stocks Mostly Lower May 12 2017 
Kahn Brothers Sells Hologic, Pfizer, Citigroup May 11 2017 
Merck Collaborates With OncoSec Medical to Unlock Untapped Market for Keytruda May 10 2017 
US Market Indexes Mostly Lower May 09 2017 
Stocks Lower With Disappointing Earnings From Apple May 03 2017 

More From Other Websites
Performance of Merck’s Diabetes Portfolio in 1Q17 May 24 2017
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk May 24 2017
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers May 24 2017
Gardasil and Merck’s Vaccines Business in 1Q17 May 24 2017
1Q17 Performance of Keytruda, Merck’s Blockbuster Drug May 24 2017
FDA Approves Merck’s Keytruda to Treat Cancers With Genetic Defects May 23 2017
FDA clears Merck's Keytruda based on cancer genetics, not location May 23 2017
Merck Presents Phase II Data on Chronic Cough Candidate May 23 2017
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable... May 23 2017
The FDA just took an entirely new approach to approving a cancer drug May 23 2017
Merck Announces Third-Quarter 2017 Dividend May 23 2017
Merck & Co.’s Segmental Performance in 1Q17 May 23 2017
Why Merck & Co. Continued to Grow in 1Q17 May 23 2017
A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings May 23 2017
UK competition watchdog accuses Merck of obstructing biosimilars May 23 2017
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for... May 23 2017
Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing May 23 2017
These Big Drug Stocks May Cure the Trump Blues May 23 2017
Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor... May 22 2017
Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? May 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}